Abstract
The emergence of new drug therapy regimens and the completion of several large randomized trials led to significant changes in the clinical guidelines of the Ministry of Health of Russia and the practical guidelines of the Russian Society of Clinical Oncology (RUSSCO) for the treatment of urologic oncology diseases. However, different interpretations of some studies by expert panels and requirements for these documents led to a divergence of some statements in these publications. The article presents executive summaries of the updated clinical and practical prostate cancer treatment guidelines.